Latest:
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Branden Moriarity, PhD
Branden Moriarity, PhD, is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the Center for Genome Engineering and the Genome Engineering Shared Resource (GESR), and a member of the Center for Genome Engineering at the University of Minnesota in Minneapolis, where he is also a faculty member in the Department of Pediatrics; the Microbiology, Immunology and Cancer Biology (MICaB) PhD Graduate Program; the PhD Program in Molecular, Cellular, Developmental Biology and Genetics; the Cellular and Molecular Biology (CMB) Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Stem Cell Institute at the Masonic Cancer Center.
Latest:
CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD
Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.
Domenica Lorusso, MD, PhD
Latest:
Dr Lorusso on the Rationale for Investigating Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Domenica Lorusso, MD, PhD, details the rationale for the ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Indiana University School of Medicine
Latest:
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural Indiana
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Angela Jain, MD
Angela Jain, MD, is an associate professor, Department of Hematology/Oncology; interim chief of the Division of Breast Medical Oncology; and chief of the Division of Gynecologic Medical Oncology, of Fox Chase Cancer Center.
Latest:
Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm
Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.
John Molina, MD, MEd
Latest:
Health Care Resource Utilization and Transition of Care
Panelists discuss routine laboratory monitoring for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) as well as insights from the American Society of Hematology Annual Meeting and Exposition (ASH 2024) data on health care resource utilization and costs associated with administering chimeric antigen receptor (CAR) T-cell therapy and managing related toxicities.
Stephen Bagley, MD, MSCE
Latest:
Monitoring DMG Treatment Response Using RANO 2.0 Criteria
Experts discuss the evolution of the Response Assessment in Neuro-Oncology (RANO) criteria culminating in RANO 2.0, which standardizes treatment response evaluation for gliomas by refining imaging benchmarks, simplifying measurement methods, and addressing challenges in distinguishing progression from treatment effects to enhance consistency in both clinical trials and routine practice.
Mitchell Machtay, MD
Latest:
Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC
Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Jennifer H. Choe, MD, PhD
Latest:
Examining the Landscape: PD-1 Inhibitors in R/M NPC
Panelists discuss the efficacy of multiple PD-1 inhibitors studied in nasopharyngeal cancer (NPC), noting similar overall outcomes despite differences in trial designs and adverse effect profiles, challenges in direct comparisons due to crossover and varying chemotherapy backbones, and how limited US approvals impact clinical choice—yet collectively these data affirm the integral role of PD-1 blockade as a cornerstone of treatment.